Scientific publications

Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology

Aug 15, 2023 | Magazine: Neoplasia

Jessica B Foster 1, Marta M Alonso 2, Elias Sayour 3, Tom B Davidson 4, Mika L Persson 5, Matthew D Dun 6, Cassie Kline 7, Sabine Mueller 8, Nicholas A Vitanza 9, Jasper van der Lugt 10


While immunotherapy for pediatric cancer has made great strides in recent decades, including the FDA approval of agents such as dinutuximab and tisgenlecleucel, these successes have rarely impacted children with pediatric central nervous system (CNS) tumors. As our understanding of the biological underpinnings of these tumors evolves, new immunotherapeutics are undergoing rapid clinical translation specifically designed for children with CNS tumors.

Most recently, there have been notable clinical successes with oncolytic viruses, vaccines, adoptive cellular therapy, and immune checkpoint inhibition. In this article, the immunotherapy working group of the Pacific Pediatric Neuro-Oncology Consortium (PNOC) reviews the current and future state of immunotherapeutic CNS clinical trials with a focus on clinical trial development. Based on recent therapeutic trials, we discuss unique immunotherapy clinical trial challenges, including toxicity considerations, disease assessment, and correlative studies. Combinatorial strategies and future directions will be addressed. Through internationally collaborative efforts and consortia, we aim to direct this promising field of immuno-oncology to the next frontier of successful application against pediatric CNS tumors.

CITA DEL ARTÍCULO Neoplasia. 2023 Aug:42:100909. doi: 10.1016/j.neo.2023.100909. Epub 2023 May 25.